Drugmaker AstraZeneca, helped by currency effects and cost savings, raised its full-year earnings forecasts on Thursday as third-quarter forecasts beat expectations.
In this Web Extra the traders talk steel and pharma stocks while also paying some attention to the Fed meeting, housing numbers, and delivering a message to Bill Gates.
Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.
You gotta feel sorry for the folks at Merck. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the ax again.
In this Web Extra find out how the traders are playing Boeing, the release of Google's new phone, Ma' Bell earnings and more.
Genentech investors who were hoping Roche would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed.
U.S. companies ranging from chemicals like Du Pont, to pharmas like Pfizer and Schering Plough, and financials like Fifth Third and BlackRock, reported earnings Tuesday.
A drug stock with a safe dividend? That's just what you need in this tough environment.
As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
On the Genentech third quarter earnings conference call analysts, investors and reporters were hoping to get some color on the status of the Roche play for the rest of DNA it doesn't already own.
Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.
In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).
Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.
With three drugs up for FDA approval by the end of the year, this stock could see a sizable increase in earnings.
Plus, Cramer speculates on where the shorts could hit next.
As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.
"The Wall Street Journal" unmasked the identity--Eli Lilly--of ImClone's secret suitor. A spokesman for LLY said he couldn't confirm or deny the report. IMCL put out a press release last night saying that the mystery bidder has asked to remain anonymous.
Congressional leaders "sweeten" the $700 billion financial rescue package to attract enough House members, particularly Republicans, to pass the plan that failed in the House just two days ago. In the meantime, billionaire investor Warren Buffett takes opportunity of the rocky markets to invest $3 Billion in GE, the parent company of CNBC. Following are today's top videos: